前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响

Effects of Alprostadil Combined with Telbivudine on Clinical Efficacy and Serum Inflammatory Factor in Patients of Hepatitis B Virus-related Cirrhosis

目的:探讨替前列地尔联合替比夫定对乙肝肝硬化患者临床效果及血清炎性因子的影响,为临床治疗提供理论依据。方法:选取本院消化内科2014年6月至2016年6月就诊的乙肝肝硬化患者98例,按随机数字表分为替比夫定组(49例)和联合组(49例)。在常规治疗的基础上,替比夫定组给予替比夫定,联合组在替比夫定的基础上给予前列地尔,治疗12周。观察两组患者治疗前后血清HBV DNA水平、肝功能及血清炎性因子的变化情况。结果:治疗后,联合组患者临床有效率高于替比夫定组(89.30%VS.63.89%,P<0.05),两组患者血清HBV DNA水平较治疗前降低(P<0.05),但是治疗后两组间差异未见统计学意义(P>0.05)。治疗后,两组患者血清AST、ALT、Tbil、IL-6、IL-22、hs-CRP的水平低于治疗前,而且联合组血清AST、ALT、Tbil、IL-6、IL-22、hs-CRP的水平明显低于替比夫定组(P<0.05)。结论:前列地尔联合替比夫定可以降低乙肝肝硬化患者血清HBV DNA的水平,改善患者肝功能和缓解炎症反应,具有良好临床疗效。

Objective: To explore clinical efficacy and serum inflammatory factor use of alprostadil combined with telbivudine in treatment of hepatitis B virus-related cirrhosis,providing a theoretical basis for clinical treatment. Methods: 98 patients with hepatitis B cirrhosis admitted in our hospital from June 2014 to June 2016,were selected. According to the random number table,patients were divided into telbivudine group( 49 cases) and combined group( 49 cases). On the basis of routine treatment,telbivudine group was given telbivudine,combined group was given telbivudine and alprostadil for 12 weeks. To observe and analyze the changes of serum HBV DNA levels,liver function and serum inflammatory factor. Results: After treatment,overall efficacy of combined group was significantly higher than that of telbivudine group( 89.30% VS.63.89%,P < 0.05).After treatment,the serum HBV and DNA levels of the two groups were significant lower than those before treatment,but there was no significant difference( P >0.05) between two groups. After treatment,serum AST,ALT,Tbil,IL-6,IL-22 and hs-CRP levels of combined group were significantly lower than those of telbivudine group( P <0.05). Conclusion: Alprostadil combined with telbivudine could reduce serum HBV DNA levels,improve liver function,and alleviate the inflammatory condition of patients with ghepatitis B virus-related cirrhosis.